title: Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups.
abstract: A three-arm randomized trial was performed to assess the acute and late toxicity and the impact on survival of the combination high-dose, split-course radiotherapy with 30 mg/m2 cisplatin (cDDP) weekly, with 6 mg/m2 cisplatin daily compared to radiotherapy alone in patients with non-small cell lung cancer (NSCLC). The study started in May 1984 and was closed in May 1989 after 331 patients were randomised. The analysis was performed after a minimum follow-up period of 22 months. Radiotherapy (RT) consisted of 30 Gy, 10 fractions, five fractions a week; then a 3-week split followed by 25 Gy in 10 fractions. Nausea and vomiting were increased for a majority of the patients in the combined treatment arms during treatment. There was no addition of bone marrow suppression, renal dysfunction or esophagitis. Increase of late radiation damage was not observed. Local control (= absence of local progression) was improved for patients treated according to the daily cisplatin arm. This has lead to an improvement in overall survival. There was no effect in time to distant metastasis due to the combined modality. The treatment influence was confirmed in the multivariate analysis.
  
  
  CONCLUSIONS
  local control and survival can be improved by combining radiotherapy with daily low-dose cisplatin in patients with inoperable NSCLC.
authors.affiliation: Netherlands Cancer Institute, Amsterdam.
authors.forename: C
authors.initials: C
authors.lastname: Schaake-Koning
authors.forename: W
authors.initials: W
authors.lastname: van den Bogaert
authors.forename: O
authors.initials: O
authors.lastname: Dalesio
authors.forename: J
authors.initials: J
authors.lastname: Festen
authors.forename: J
authors.initials: J
authors.lastname: Hoogenhout
authors.forename: P
authors.initials: P
authors.lastname: van Houtte
authors.forename: A
authors.initials: A
authors.lastname: Kirkpatrick
authors.forename: M
authors.initials: M
authors.lastname: Koolen
authors.forename: B
authors.initials: B
authors.lastname: Maat
authors.forename: A
authors.initials: A
authors.lastname: Nijs
mesh_terms: D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000209:etiology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004941:Esophagitis / Q000209:etiology; D005260:Female; D006801:Humans; D015993:Life Tables; D008171:Lung Diseases / Q000209:etiology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D016016:Proportional Hazards Models; D011832:Radiation Injuries / Q000209:etiology; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin